** Shares of clinical-stage biopharmaceutical firm Radiopharm Theranostics RAD.AX rise as much as 21.7% to A$0.028, their highest since Dec. 16
** Co inks co-development deal to develop biopharmaceuticals with Massachusetts-based Lantheus LNTH.O in Australia
** Deal includes basket clinical trial targeting multiple solid tumours
** Co to receive up to $2 mln in milestone payments upon achieving key objectives, with the LNTH footing all costs
** Including session's moves, stock trims YTD losses to 64.9% as of 2340 GMT
(Reporting by Kumar Tanishk in Bengaluru)
((Tanishk.Kumar@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。